Law & policy

Latest content

Draft Biden SEP policy favours implementers, but even they may still flock to other jurisdictions

Finnegan attorneys Erik Puknys and Michelle Rice explain that while the proposed DOJ/NIST/USPTO FRAND framework is good for implementers, it may not be enough to make the US stand out in global forum competition

17 January 2022

Without injunctions, the US patent system is rigged in favour of deep pocket defendants

Sonos’s recent win over Google at the ITC demonstrates the importance of innovators having the ability to exclude infringers from practising on their inventions

14 January 2022

mRNA vaccines: how to navigate the freedom-to-operate maze

The Long Read: Jeffrey Morton and Thomas Ehrich unpack the complex patent considerations surrounding one of the most important leaps forward in biotechnology

12 January 2022

Rise of AI continues to re-write life sciences IP strategies in 2022

A spate of pharma-high tech innovation partnerships have dominated opening days of the year

11 January 2022

Tencent, Vivo among biggest risers as Chinese patent grants continue to grow

The number of invention patents and utility models issued by the CNIPA both surged by more than 30% last year, while PCT filings levelled off

11 January 2022

AbbVie heads to the ITC in dramatic final battle over Humira biosimilars

Chicago-based company seeking to exclude Alvotech’s adalimumab product from the US market for alleged trade secret misappropriation

10 January 2022

Vidal USPTO Director confirmation vote cancelled, but not due to opposition to her appointment

The Senate Judiciary Committee is all set to endorse her appointment but has been delayed in doing thanks to a funeral and a riot’s anniversary

06 January 2022

Landmark Dutch appeal court decision reduces risk of third-party damages against pharma patentees

The appellate ruling overturns a recent lower court judgment which exposed life sciences IP plaintiffs to significant additional dangers from health insurer lawsuits

06 January 2022

How looming patent cliffs are impacting pharma IP strategies

Major IP expiries on the horizon are not only shaping pharma dealmaking patterns, but are likely to lead to further patent thicket disputes.

05 January 2022

Huawei inks its first Wi-Fi 6 patent licence with an overseas implementer

Latest patent deals related to the next-gen wireless internet standard suggest patent owners spy monetisation opportunities

04 January 2022

Get unlimited access to all IAM content